Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial …
S Glatt, D Baeten, T Baker, M Griffiths… - Annals of the …, 2018 - ard.bmj.com
Objective Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-
mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and …
mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and …
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
L Bueno, DP de Alwis, C Pitou, J Yingling… - European journal of …, 2008 - Elsevier
Human xenografts Calu6 (non-small cell lung cancer) and MX1 (breast cancer) were
implanted subcutaneously in nude mice and LY2157299, a new type I receptor TGF-β …
implanted subcutaneously in nude mice and LY2157299, a new type I receptor TGF-β …
First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
S Glatt, E Helmer, B Haier… - British journal of …, 2017 - Wiley Online Library
Aims To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL) …
Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high
burden for patients and limited existing therapeutic options. Objective To evaluate the …
burden for patients and limited existing therapeutic options. Objective To evaluate the …
Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans
WJ Winchester, K Gore, S Glatt, W Petit… - … of Pharmacology and …, 2014 - ASPET
The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation
channel localized in primary sensory neurons, and is a candidate for cold thermosensing …
channel localized in primary sensory neurons, and is a candidate for cold thermosensing …
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
S Glatt, PC Taylor, IB McInnes, G Schett… - Annals of the …, 2019 - ard.bmj.com
Objective Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-
17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) …
17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) …
[HTML][HTML] Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
E De Leeuw, KFA Van Damme, J Declercq… - Respiratory …, 2022 - Springer
Background The efficacy and safety of complement inhibition in COVID-19 patients is
unclear. Methods A multicenter randomized controlled, open-label trial. Hospitalized COVID …
unclear. Methods A multicenter randomized controlled, open-label trial. Hospitalized COVID …
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models
I Gueorguieva, K Ogungbenro, G Graham… - Computer methods and …, 2007 - Elsevier
The design of pharmacokinetic and pharmacodynamic experiments concerns a number of
issues, among which are the number of observations and the times when they are taken …
issues, among which are the number of observations and the times when they are taken …
A cross-species translational pharmacokinetic-pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF-05105679
JR Gosset, K Beaumont, T Matsuura… - European Journal of …, 2017 - Elsevier
PF-05105679 is a moderately potent TRPM8 blocker which has been evaluated for the
treatment of cold pain sensitivity. The TRPM8 channel is responsible for the sensation of …
treatment of cold pain sensitivity. The TRPM8 channel is responsible for the sensation of …
Characterization of a surrogate murine antibody to model anti-human CD3 therapies
Fc-modified anti-human CD3ε monoclonal antibodies (mAbs) are in clinical development for
the treatment of autoimmune diseases. These next generation mAbs have completed clinical …
the treatment of autoimmune diseases. These next generation mAbs have completed clinical …